Predicting Failure of Glyburide Therapy in Gestational Diabetes

Lorie M. Harper, MD, MSCI1, Angelica V. Glover, MD1, Joseph R. Biggio, MD1, and Alan Tita, MD, PhD1

1The University of Alabama at Birmingham, Center for Women’s Reproductive Health, Department of Obstetrics and Gynecology, Birmingham, AL

Abstract

Objective—We sought to develop a prediction model to identify women with gestational diabetes (GDM) who require insulin to achieve glycemic control.

Study Design—Retrospective cohort of all singletons with GDM treated with glyburide 2007–2013. Glyburide failure was defined as reaching glyburide 20 mg/day and receiving insulin. Glyburide success was defined as any glyburide dose without insulin and >70% of visits with glycemic control. Multivariable logistic regression analysis was performed to create a prediction model.

Results—Of 360 women, 63 (17.5%) qualified as glyburide failure and 157 (43.6%) glyburide success. The final prediction model for glyburide failure included prior GDM, GDM diagnosis ≤26 weeks, 1-hour GCT ≥228 mg/dL, 3-hour GTT 1-hour value ≥221 mg/dL, ≥7 post-prandial blood sugars >120 mg/dL in the week glyburide started, and ≥1 blood sugar >200 mg/dL. The model accurately classified 81% of subjects.

Conclusions—Women with GDM who will require insulin can be identified at initiation of pharmacologic therapy.

Introduction

In 2000, Langer et al published a randomized control trial comparing glyburide and insulin for the treatment of gestational diabetes (GDM).1 They demonstrated that glyburide and insulin achieve similar levels of maternal glycemic control. Given that glyburide is significantly easier to use and less expensive than insulin, glyburide has become a first-line therapy for many clinicians for the treatment of GDM. The use of glyburide to treat GDM has increased dramatically since 2001, increasing from 7.4% of prescriptions to treat GDM to 64.5% in 2011.2 However, several retrospective studies have found an increased risk of macrosomia or large for gestational age infants in women receiving glyburide compared to...
those receiving insulin.\textsuperscript{3,4,5} Other retrospective studies have found a higher incidence of preeclampsia in women treated with glyburide compared to insulin.\textsuperscript{6,7}

These increased adverse perinatal outcomes in women treated with glyburide may be due to delays in glycemic control in those who ultimately fail glyburide therapy and require treatment with insulin. This situation arises in 5–20\% of women who require medical therapy for GDM.\textsuperscript{1,8,9,10} Delay of insulin initiation may result in weeks of hyperglycemia and subsequently increased risks of adverse perinatal outcomes.

We therefore aimed to develop a prediction model for glyburide failure based on factors known at the time of initiation of medical therapy for GDM in order to optimize therapy for women requiring medical therapy. We hypothesized that failure of glyburide therapy can be predicted at the time that pharmacotherapy for GDM is initiated.

**Materials and Methods**

We conducted a retrospective cohort study of all singletons diagnosed with GDM and treated with glyburide at the University of Alabama at Birmingham Jan 1, 2007–Dec 31, 2013. Institutional review board approval was obtained.

Subjects were identified from the searchable electronic medical record system using a diagnosis of gestational diabetes and diabetes; a diagnosis of gestational diabetes was confirmed on review of medical records. The protocol for diagnosing gestational diabetes is to perform a 1-hour glucose tolerance test on all women; if $\geq 35$ mg/dL a 3-hour glucose tolerance is performed. Subjects were considered to have gestational diabetes if a 3-hour glucose tolerance test was performed and met Carpenter-Coustan criteria,\textsuperscript{11} if a 1-hour glucose challenge test was $\geq 200$ mg/dL, or if fasting blood sugar was $\geq 20$ mg/dL. Trained personnel (obstetricians and medical students) reviewed medical records to abstract detailed patient data using standardized data collection forms. Abstracted data included maternal age, ethnicity, socioeconomic status, self-reported prepregnancy height and weight, comorbid medical conditions, obstetric history, blood sugar testing, gestational weight gain, prenatal blood sugar logs, delivery details, and perinatal outcomes.

At UAB, women with gestational diabetes are managed by Maternal-Fetal Medicine specialists. Women are screened at the recommended time of 24–28 weeks estimated gestation. Women with risk factors for gestational diabetes, such as obesity or a prior history of gestational diabetes may be screened earlier at the discretion of the provider. All women diagnosed with gestational diabetes receive individualized nutrition counseling and are advised to check their blood sugars fasting and 2-hours after each meal. Women are typically seen at 1 week intervals until glycemic targets are reached, and then may have visits every other week until 34–36 weeks. Glycemic targets are fasting blood sugar $< 95$ mg/dL and 2-hour post-prandial blood sugars $< 120$ mg/dL. Women are started on a pharmacologic agent for gestational diabetes if $> 50\%$ of fasting or post-prandial blood sugars are elevated. Since 2007, glyburide has been the first-line agent at UAB for gestational diabetes. At UAB, glyburide is typically started at 2.5–5 mg/day (in single or divided dosing) and increased by 2.5–5 mg/day. However, use of glyburide and its dosing
was at the discretion of the attending physician; some patients may have been initiated on
other pharmacologic agents such as metformin or insulin as the first line.

Subjects were included in this analysis if they were diagnosed with GDM and received
glyburide for glycemic control. Subjects were excluded from this analysis if comorbid
conditions other than chronic hypertension were present (eg systemic lupus erythematosus,
HIV, hepatitis), any fetal anomaly was diagnosed, or if presentation for prenatal care was
late (>26 weeks).

Glyburide failure was defined as reaching 20 mg/day of glyburide and then receiving insulin
therapy. Glyburide success was defined as those treated with any dose of glyburide without
receiving insulin and who had demonstrated glycemic control at >70% of visits. As the
median number of visits after starting pharmacotherapy was 6 (interquartile range 4–9); a
marker of 70% allowed for 1 visit with poor control and/or medication adjustment.
Additionally, at least 3 fasting and 3 post-prandial blood sugars had to be recorded to be
considered in the glyburide success group. The group that was neither a glyburide failure or
success, i.e. those that were continued on glyburide without receiving insulin and had fewer
than 70% of prenatal visits without blood sugar control, were classified as poorly controlled
on glyburide and excluded from analysis.

We determined factors that were significantly associated with glyburide failure in a
univariate analysis. Only factors known at the time glyburide was initiated were considered
in the analysis. Factors considered included maternal age, prepregnancy body mass index,
race, education, insurance, prior pregnancy history including a history of GDM in a prior
pregnancy, gestational age at diagnosis, gestational weight gain, one-hour and three-hour
glucose challenge test results, and blood sugar log records the week prior to starting
glyburide. The Liu method\textsuperscript{12} was used to identify an optimal cut point for continuous
variables.

Groups were compared using Student’s t-test or chi-square test as appropriate. Clinically
relevant covariates for initial inclusion in multivariable models were selected using the
results of the stratified analyses, and factors were removed in backwards stepwise fashion,
based on significant changes in the exposure adjusted odds ratio or significant differences
between hierarchical models using the likelihood ratio test. The cutoff point was selected to
minimize false-positive diagnoses; in other words, specificity for correctly identifying
glyburide failure was more important than sensitivity for identifying glyburide failure.
Receiver operator characteristics curves were created to estimate the predictive value of the
final model. The internal validity of the model was then assessed using bootstrapping over
5,000 replications. All analyses were performed using STATA SE, version 13.0 (College
Station, TX).

**Results**

Of 1,212 women identified with GDM, 145 were excluded for being unable to confirm a
diagnosis of GDM with laboratory testing, 82 for major medical comorbidities, 29 for fetal
anomalies, 61 for late prenatal care and 493 for being managed by diet therapy alone,
leaving 402 subjects for analysis. Of these 402 subjects, only 39 were initiated directly on insulin (for suspicion of pregestation diabetes) and 3 on metformin, leaving 360 subjects with A2 GDM initiated on glyburide after diet failure (Figure 1). Of the 360 subjects, 63 (17.5%) were classified as glyburide failure and 157 (43.6%) as glyburide success. The remaining 140 (38.9%) were managed on glyburide alone without meeting the success criteria of >70% of prenatal visits with blood sugar control.

Those successfully managed on glyburide and those failing glyburide were similar with regards to maternal age, race, nulliparity, chronic hypertension, prepregnancy body mass index, prior cesarean, and prior macrosomic infant (Table 1). Women who failed glyburide therapy were less likely to have public health insurance and more likely to smoke or to have had GDM in a prior pregnancy. With regards to pregnancy and GDM diagnosis, women who failed glyburide therapy were diagnosed at an earlier gestational age, had higher 1-hour glucose challenge test values, higher fasting and one-hour values on the three-hour glucose tolerance test (Table 2). On blood sugar logs on the week prior to initiating glyburide, women who failed glyburide had more fasting blood sugars >100 mg/dL, more post-prandial values >120 mg/dL, and more blood sugars >200 mg/dL. Gestational weight gain until initiation of glyburide was similar between groups.

We then built a multivariate model to predict glyburide failure versus glyburide success. Factors significant in the final model are demonstrated in Table 3 and Box 1 and include GDM in a prior pregnancy, gestational age at diagnosis ≤26 weeks, a 1 hour glucose challenge test value ≥228 mg/dL, a 1-hour value on the three hour glucose tolerance test ≥221, 7 or more 2-hour postprandial blood sugars >120 mg/dL on blood sugar log for the week prior, 1 or more blood sugar >200 mg/dL on blood sugar log for the week prior. This model classified women as glyburide failure if the calculated risk of failure based on the equation in Box 1 was ≥75%. As each factor was added to the model, the percentage of women correctly classified increased, as did the sensitivity and specificity. The final model correctly classified 80.9% of women, with a sensitivity of 39.7% and a specificity of 97.5%. The area under the curve for this model was 0.86 (Figure 2). Over 5,000 iterations, the sensitivity of the model ranged from 32.3–40.3% and the specificity ranged from 97.4–99.4%. The area under the curve for the model over 5,000 iterations ranged from 0.86–0.87, demonstrating that this model is robust.

Because early gestational age at diagnosis and a 1 hour glucose challenge test value >200 mg/dL are frequently considered markers of pregestational diabetes, we re-evaluated the prediction model excluding subjects with either of these markers. Of the 98 subjects remaining, 13 failed glyburide therapy and 85 achieved good glucose control on glyburide. The model predicts glyburide failure with 30.8% sensitivity and 98.8% specificity and an area under the curve of 0.87.

When this model was applied to all 360 women started on glyburide (including the 140 women in the poorly controlled on glyburide category), 40 (11%) women were predicted to have a glyburide failure. Of these 40, 25 (62.5%) failed glyburide and 4 (10%) were poorly controlled on glyburide. If this model were applied prospectively, only 11 (3.1%) women would have been falsely predicted as glyburide failure.
Discussion

The majority of women who will reach a maximum dose of glyburide without achieving glycemic control can be identified at the time glyburide is initiated. We developed a prediction model with a specificity of 97.5% for those who will fail glyburide therapy and require insulin therapy. This prediction model classified only 11% of our subjects as glyburide failure with a low false positive rate.

The trade-off of the model having a high specificity is a relatively low sensitivity of only 40%. However, we feel that a sensitivity of 40% of women who will fail glyburide being identified by the model is a vast improvement over initiating a patient on glyburide and waiting several weeks to determine success or failure of treatment. Additionally, we purposely elected to build a model with an emphasis on specificity for several reasons. First, patients prefer glyburide to insulin as it is easier and less painful. Secondly, glyburide is significantly less expensive than insulin and does not require additional visits for diabetic education. Therefore, we felt a model that is more specific (fewer predictions of glyburide failure when glyburide may succeed) was preferable to a model that was more sensitive.

Several factors included in the model may actually be associated factors associated with pregestational diabetes, such as extremely elevated fasting values, a one hour glucose challenge test >200 mg/dL, a prior pregnancy complicated by gestational diabetes, or an early gestational age at diagnosis. However, because these women were diagnosed during pregnancy and had no known history of diabetes outside of pregnancy, we included them in the cohort. As many women first diagnosed during pregnancy may be considered for a trial of oral medications, particularly as they are unlikely to be familiar with insulin, this is representative of clinical practice. Indeed, these patients are those who will most likely benefit from aggressive treatment of blood sugars by direct initiation on insulin without a trial of glyburide. Additionally, when we applied the model to a cohort of women excluding markers of pregestational diabetes, the model continued to perform robustly, with a specificity of 98.8%.

Several prior studies have examined risk factors for requiring insulin therapy for glycemic control in GDM. In a prospective study, Chmait et al determined that the most important markers of glyburide failure were gestational age (<30 weeks) and mean blood glucose values (fasting blood sugar >110 mg/dL, 1-hour post-prandial values >140 mg/dL) at initiation of glyburide. However, the chosen criteria in this study were only 65% specific for identifying glyburide success or failure. This would lead to a falsely identifying glyburide failure in almost 1/3 of patients in the population, potentially using the more expensive and more cumbersome insulin in women who could achieve glycemic control with glyburide. Another study to identify predictors glyburide failure versus glyburide success confirm the importance of gestational age at glyburide initiation, but found that gestational at diagnosis prior to 25 weeks (as opposed to 30 weeks) was associated with an 8-fold increase in the risk of glyburide failure. Other important predictors were maternal age and multiparity. Rochon et al also sought to identify factors predictive of glyburide failure. In this study, glyburide failure was defined as anybody who was started on glyburide and switched to insulin, not just women who failed to achieve glycemic control on
a maximum dose of glyburide and switched to insulin. Unlike other studies, gestational age at diagnosis was not significantly associated with glyburide failure. Factors associated with glyburide failure included a glucose challenge test value greater than 200 mg/dL and a fasting blood sugar value greater than 95 mg/dL.

Our study has several strengths. First, we had a large number (n=63) of women who failed glyburide therapy. This is approximately 3–5 times larger than other studies we identified in the literature of women who failed glyburide therapy. This enabled us to investigate multiple factors involved in glyburide failure simultaneously. Additionally, we had detailed patient level data that included GDM testing results and blood sugar logs for the entire pregnancy. This detailed data enabled us to consider a multitude of factors that may be important in determining glyburide failure, including blood sugar values the week prior to glyburide initiation. Furthermore, we considered only factors known at the time glyburide was initiated in the prediction model. Although information obtained later in pregnancy may also be associated with glyburide failure, this information is not available to clinicians at the time of the decision to initiate glyburide or insulin; consequently, it does not belong in a clinically useful prediction model. We used an empiric method (the Liu method) to define optimal thresholds of continuous variables to use in our prediction model, rather than outcomes considered clinically important traditionally (i.e. a glucose challenge test of 200 mg/dL or gestational age prior to 20 weeks). Consequently, we optimized the sensitivity and specificity of our model. Finally, a stringent definition of glyburide failure (i.e. reaching a dose of 20 mg/day of glyburide and initiation on insulin) and glyburide success (i.e. >70% of visits with glycemic control) was used, limiting misclassification bias due to provider judgment or patient preferences for glyburide versus insulin.

One potential weakness of this study is that we excluded subjects who were poorly controlled on glyburide when developing our prediction model, thus excluding 39% of the cohort. We did this for several reasons. First, the goal of initiating glyburide is to achieve glycemic control. Thus, the ideal comparison group to failing glyburide therapy is a group of women who actually achieved glycemic control with glyburide. Also, in a retrospective study, it is unclear if the excluded group represents glyburide success or failure. Although we collected significant amounts of detailed patient-level information (including weekly blood sugar logs and medication doses), we did not collect data on information such as patient refusal of insulin or patient’s access to medication. Therefore, some may have had improved blood sugar control with simply higher doses of glyburide, others may have actually been recommended to start insulin but refused or delivered before it could be initiated. Therefore, exclusion of this group likely avoided some misclassification bias. When this group of women was included and the model applied, the model continued to perform well with a low positive rate. Finally, although our clinical practice typically gives every patient a trial of glyburide, some patients (less than 10%) were initiated on insulin without first receiving glyburide therapy. Their exclusion may have impacted the model by excluding women most likely to fail glyburide therapy, although this may be preferred as it mimics what happens in clinical practice. Women who were initiated directly on insulin without a trial of glyburide were more likely to have had a prior pregnancy complicated by GDM than those given a trial of glyburide, but were otherwise similar with respect to age.
prepregnancy BMI, and race (data available upon request). Therefore, we do not feel that their exclusion significantly altered our results.

In sum, we have developed a prediction model based on factors known at the time of glyburide initiation to predict those who will ultimately fail glyburide therapy and require insulin. This model has excellent specificity in order to avoid initiating insulin in a patient who could achieve glycemic control with glyburide therapy. Application of this model prospectively should be investigated to determine if starting women at high risk of glyburide failure directly on insulin can improve perinatal outcomes.

Acknowledgments

Dr. Harper is supported by K12HD001258-13, PI WW Andrews, which partially supports this work.

References

1. Langer O, Conway DL, Berkus MD, Xenakis EM, Gonzales O. A comparison of glyburide and insulin in women with gestational diabetes mellitus. The New England journal of medicine. 2000; 343(16):1134–1138. [PubMed: 11036118]
2. Camelo Castillo W, Boggess K, Sturmer T, Brookhart MA, Benjamin DK Jr, Jonsson Funk M. Trends in glyburide compared with insulin use for gestational diabetes treatment in the United States, 2000–2011. Obstetrics and gynecology. 2014; 123(6):1177–1184. [PubMed: 24807336]
3. Cheng YW, Chung JH, Block-Kurbisch I, Inturrisi M, Caughey AB. Treatment of gestational diabetes mellitus: glyburide compared to subcutaneous insulin therapy and associated perinatal outcomes. The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstet. 2012; 25(4):379–384.
4. Bertini AM, Silva JC, Taborda W, Becker F, Lemos Bebber FR, Zucco Viesi JM, et al. Perinatal outcomes and the use of oral hypoglycemic agents. Journal of perinatal medicine. 2005; 33(6):519–523. [PubMed: 16318615]
5. Camelo Castillo W, Boggess K, Sturmer T, Brookhart MA, Benjamin DK Jr, Jonsson Funk M. Association of Adverse Pregnancy Outcomes With Glyburide vs Insulin in Women With Gestational Diabetes. JAMA pediatrics. 2015; 169(5):452–458. [PubMed: 25822253]
6. Jacobson GF, Ramos GA, Ching JY, Kirby RS, Ferrara A, Field DR. Comparison of glyburide and insulin for the management of gestational diabetes in a large managed care organization. American journal of obstetrics and gynecology. 2005; 193(1):118–124. [PubMed: 16021069]
7. Joy S, Roman A, Istwan N, Rhea D, Desch C, Stanziano G, et al. The effect of maternal obesity on pregnancy outcomes of women with gestational diabetes controlled with diet only, glyburide, or insulin. American journal of perinatology. 2012; 29(8):643–648. [PubMed: 22644829]
8. Chaintait R, Dinise T, Moore T. Prospective observational study to establish predictors of glyburide success in women with gestational diabetes mellitus. Journal of perinatology : official journal of the California Perinatal Association. 2004; 24(10):617–622. [PubMed: 15152273]
9. Kahn BF, Davies JK, Lynch AM, Reynolds RM, Barbour LA. Predictors of glyburide failure in the treatment of gestational diabetes. Obstetrics and gynecology. 2006; 107(6):1303–1309. [PubMed: 16738156]
10. Rochon M, Rand L, Roth L, Gaddipati S. Glyburide for the management of gestational diabetes: risk factors predictive of failure and associated pregnancy outcomes. American journal of obstetrics and gynecology. 2006; 195(4):1090–1094. [PubMed: 17000241]
11. ACOG Committee on Practice Bulletins; ACOG. Practice Bulletin No. 137: Gestational diabetes mellitus. Obstetrics and gynecology. 2013; 122(2 Pt 1):406–416. [PubMed: 23969827]
12. Liu X. Classification accuracy and cut point selection. Statistics in medicine. 2012; 31(23):2676–2686. [PubMed: 22307964]
Box 1

Logistic Regression Equation for Prediction of Glyburide Failure

\[
\text{Predicted probability of glyburide failure} = \frac{exp(w)}{1+exp(w)} \quad \text{where}
\]

\[
w = -3.864063 + 1.589964 \times (\text{GDM in a Prior Pregnancy}) + 0.6698857 \times (\text{Gestational Age at Diagnosis} \leq 26 \text{ weeks}) + 1.059195 \times (\text{Glucose Challenge Test} \geq 228 \text{ mg/dL}) + 1.1380658 \times (\text{on 3-hour Glucose tolerance test, a 1-hour value} \geq 221 \text{ mg/dL}) + 1.471988 \times (\text{≥7 Post-Prandial Blood Sugars} > 120 \text{ on Log for the Week Prior}) + 1.312223 \times (\text{≥1 Blood Sugars} > 200 \text{ on Log for the Week Prior})
\]

For each variable, replace variable name with 1 if “yes” or 0 if “no”
1,212
Singleton Pregnancies Complicated by GDM

Exclusion:
145 No Diagnostic Tests Available
82 Major Medical Problems
29 Fetal Anomalies
61 Late Prenatal Care
493 A1 GDM

39
Initiated on Insulin without Trial of Glyburide

360
Initiated on Glyburide

3
Initiated on Metformin

63
Glyburide Failure

140
Glyburide Alone with Poor Control

157
Glyburide Success

Figure 1.
Flow Diagram of Patients in Cohort
Figure 2.
Receiver Operator Characteristics Curve for Prediction Model of Glyburide Failure
### Table 1
Maternal Characteristics Associated with Glyburide Failure

|                      | Glyburide Successful | Glyburide Failure | p       |
|----------------------|----------------------|-------------------|---------|
|                      | N=157                | N=63              |         |
| Maternal Age (years) | 29.7 ± 5.8           | 30.1 ± 5.1        | 0.51    |
| Race                 |                      |                   |         |
| Black                | 80 (55.6%)           | 33 (52.4%)        | 0.38    |
| White                | 15 (10.4%)           | 12 (19.0%)        |         |
| Hispanic             | 47 (32.6%)           | 16 (25.4%)        |         |
| Other                | 2 (1.4%)             | 2 (3.2%)          |         |
| Nulliparity          | 47 (29.9%)           | 14 (22.2%)        | 0.25    |
| Chronic Hypertension | 23 (14.7%)           | 11 (17.5%)        | 0.6     |
| Prepregnancy BMI (kg/m²) | 35.0 ± 8.6     | 35.4 ± 8.2        | 0.78    |
| Obese (Unknown BMI in 7 subjects) | 115/153 (75.2%) | 44/60 (73.3%) | 0.78 |
| Tobacco Use          | 17 (10.8%)           | 15 (23.8%)        | 0.01    |
| Public Health Insurance | 125 (79.6%)       | 40 (63.5%)        | <0.01   |
| Prior Gestational Diabetes | 22 (14.0%)     | 30 (47.6%)        | <0.01   |
| Prior Macrosomic Infant | 21 (13.4%)        | 7 (11.1%)         | 0.65    |
| Prior Cesarean       | 41 (26.1%)           | 19 (30.2%)        | 0.54    |
| Number of Visits after Glyburide Initiation | 6 (4–8) | 9 (7–14) | <0.01 |

Data presented as mean ± standard deviation or n(%)
### Table 2

**Pregnancy Characteristics Associated with Glyburide Failure**

|                                      | Glyburide Successful | Glyburide Failure | p   |
|--------------------------------------|----------------------|-------------------|-----|
|                                      | N=157                | N=63              |     |
| Gestational Age at Diagnosis (weeks) | 25.7 ±3.7            | 19.6 ± 7.8        | <0.01 |
| Gestational Weight Gain until Glyburide Started | 7.4 ± 6.9          | 6.8 ± 8.8         | 0.6  |
| 1-Hour GCT Level                     | 189 ± 33             | 228 ± 66          | <0.01 |
| 1-Hour GCT >200 mg/dL                | 59 (37.6%)           | 43 (68.3%)        | <0.01 |
| 3-Hour GCT Results                   |                      |                   |     |
|                                      | Fasting              |                   |     |
|                                      | 106 ± 15             | 138 ± 52          | <0.01 |
|                                      | 1-Hour               |                   |     |
|                                      | 201 ± 28             | 218 ± 31          | 0.02 |
|                                      | 2-Hour               |                   |     |
|                                      | 178 ± 28             | 188 ± 42          | 0.25 |
|                                      | 3-Hour               |                   |     |
|                                      | 140 ± 27             | 143 ± 42          | 0.75 |
| Blood Sugars on Diet                 |                      |                   |     |
|                                      | Number of Fastings >100 mg/dL | 2 (1–3)         | 4 (1–6)  | <0.01 |
|                                      | Number of Post-Prandial >120 mg/dL | 3 (1–6)        | 8 (5–11)  | <0.01 |
|                                      | Number of Blood Sugars >200 mg/dL | 0 (0–0)        | 0 (0–1)   | <0.01 |

Data presented as mean ± standard deviation, n(%), or median (interquartile range)
Table 3
Odds Ratios, Sensitivities, and Specificities for Components of Prediction Model

|                          | Odds Ratio (95% CI) | Correctly Classified Cumulative | Sensitivity Cumulative | Specificity Cumulative |
|--------------------------|---------------------|---------------------------------|------------------------|------------------------|
| GDM in Prior Pregnancy   | 4.90 (2.0–11.8)     | 71.40%                          | 0%                     | 100%                   |
| Gestational Age at Diagnosis ≤26 weeks | 1.95 (0.87–4.38)     | 71.40%                          | 0%                     | 90.50%                 |
| 1-Hour Glucose challenge Test ≥228 mg/dL | 2.88 (1.29–6.45) | 77.70%                          | 28.60%                 | 97.50%                 |
| On 3-hour Glucose tolerance test, a 1-hour value ≥221 mg/dL | 3.12 (1.21–8.07) | 77.70%                          | 27.00%                 | 98.10%                 |
| ≥ Post-Prandial Blood Sugars >120 on Log for the Week Prior | 4.36 (1.83–10.4) | 80.90%                          | 36.50%                 | 98.70%                 |
| ≥ Blood Sugars >200 on Log for the Week Prior | 3.7 (1.36–10.16) | 80.90%                          | 39.70%                 | 97.50%                 |
| Final Model              |                     | 80.90%                          | 39.70%                 | 97.50%                 |

Percentages given for Correctly Classified, Sensitivity, and Specificity are for models built using the variable in the row as well as all rows above. For example, numbers given for gestational age at diagnosis ≤26 weeks include gestational age as well as GDM in prior pregnancy.